Lamotrigine (All indications) updated on 04-22-2025

Postpartum hemorrhage

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18701
R79550		 Mazzone (Lamotrigine) (Mixed indications), 2025 Postpartum hemorrhage during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.04 [0.89;1.21] 500/1,469   203,226/624,794 203,726 1,469
ref
S8957
R30337		 Borthen (Lamotrigine) (Controls unexposed, disease free), 2010 Haemorrhage ≥ 500 ml during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.60 [1.20;2.20]
excluded (control group) 		48/233   49,252/362,302 49,300 233
ref
S8959
R30345		 Borthen (Lamotrigine) (Controls unexposed, sick), 2010 Haemorrhage ≥ 500 ml during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No 1.49 [1.06;2.10] C 48/233   276/1,863 324 233
ref
Total 2 studies 1.20 [0.85;1.70] 204,050 1,702
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Mazzone (Lamotrigine) (Mixed indications), 2025Mazzone, 2025 1 1.04[0.89; 1.21]203,7261,46959%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Borthen (Lamotrigine) (Controls unexposed, sick), 2010Borthen, 2010 2 1.49[1.06; 2.10]32423341%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 72% 1.20[0.85; 1.70]204,0501,7020.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Mixed indications; 2: Lamotrigine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.20[0.85; 1.70]204,0501,70272%NAMazzone (Lamotrigine) (Mixed indications), 2025 Borthen (Lamotrigine) (Controls unexposed, sick), 2010 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.04[0.89; 1.21]203,7261,469 -NAMazzone (Lamotrigine) (Mixed indications), 2025 1 unexposed, sickunexposed, sick 1.49[1.06; 2.10]324233 -NABorthen (Lamotrigine) (Controls unexposed, sick), 2010 1 Tags Adjustment   - No  - No 1.49[1.06; 2.10]324233 -NABorthen (Lamotrigine) (Controls unexposed, sick), 2010 1   - Yes  - Yes 1.04[0.89; 1.21]203,7261,469 -NAMazzone (Lamotrigine) (Mixed indications), 2025 1 All studiesAll studies 1.20[0.85; 1.70]204,0501,70272%NAMazzone (Lamotrigine) (Mixed indications), 2025 Borthen (Lamotrigine) (Controls unexposed, sick), 2010 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 8957

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.26[0.83; 1.92]253,0261,70284%NAMazzone (Lamotrigine) (Mixed indications), 2025 Borthen (Lamotrigine) (Controls unexposed, disease free), 2010 2 unexposed, sick controlsunexposed, sick controls 1.49[1.06; 2.10]324233 -NABorthen (Lamotrigine) (Controls unexposed, sick), 2010 10.510.01.0